Netherlands: Weekly Stock Market Performance Insight - January 12 - 18, 2026

Euronext N.V takes a breather following a 3-week decline (126.10 → 121.80), down 3.4%. However, fundamentals remain robust: 465.4M revenue generating 196.5M profit (42.2% margin) as of Qtr ending Jun 2025 suggests this could be a temporary setback. Value hunters take note.

Stellantis N.V consolidates with a 2-week decline (11.30 → 9.60), down 15.0%. Weak margins on 28.6B revenue with only 1.6B profit (5.5% margin) in Qtr ending Dec 2020 validate market skepticism. Structural improvements needed before sentiment shifts.

NewAmsterdam Pharma pulls back after a 3-week decline (34.90 → 31.65), down 9.3%. Financial struggles compound the decline: despite 3.0M revenue, - 39.5M losses persist (-1327.3% margin) as of Qtr ending Mar 2025. Until profitability improves, caution remains warranted.

Envipco Holding N.V takes a breather following a 2-week decline (5.50 → 4.51), down 18.0%. Financial struggles compound the decline: despite 23.1M revenue, - 2.5M losses persist (-10.9% margin) as of Qtr ending Jun 2025. Until profitability improves, caution remains warranted.

Uniqure N.V consolidates with a 1-week decline (25.09 → 22.84), down 9.0%. Financial struggles compound the decline: despite 3.7M revenue, - 80.5M losses persist (-2175.9% margin) as of Qtr ending Sep 2025. Until profitability improves, caution remains warranted.

Pharming Group N.V consolidates with a 1-week decline (18.93 → 18.44), down 2.6%. Weak margins on 97.3M revenue with only 7.5M profit (7.8% margin) in Qtr ending Sep 2025 validate market skepticism. Structural improvements needed before sentiment shifts.